ATRC vs RMD
ATRC: AtriCure provides specialized surgical solutions and cryotherapy devices for the treatment of atrial fibrillation and the management of post-operative pain. RMD: ResMed is a leader in connected medical technology providing digital health solutions and innovative devices to improve the lives of people with sleep-disordered breathing and chronic respiratory conditions.
Side-by-side fundamentals
| Metric | ATRC | RMD | Edge |
|---|---|---|---|
| Price as of 2026-08-07 close | $41.39 | $211.94 | |
| Market cap as of 2026-08-09 | $2.1B | $30.7B | |
| P/E as of 2026-08-09 | 199.52 | 20.23 | RMD lower |
| PEG as of 2026-08-09 | n/a | 2.20 | |
| Net margin as of 2026-08-09 | +1.9% | +27.4% | RMD higher |
| Gross margin as of 2026-08-09 | +76.3% | +61.6% | ATRC higher |
| Operating margin as of 2026-08-09 | +2.3% | +34.2% | RMD higher |
| ROE as of 2026-08-09 | +2.1% | +24.4% | RMD higher |
| ROA as of 2026-08-09 | +1.6% | +18.0% | RMD higher |
| Debt / equity as of 2026-08-09 | 0.13 | 0.10 | RMD lower |
| Revenue growth (YoY) as of 2026-08-09 | +13.9% | +10.3% | ATRC higher |
| Revenue CAGR (3y) SEC XBRL | +17.4% | +12.9% | ATRC higher |
| Dividend yield as of 2026-08-09 | n/a | +1.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-08-09 | 1.26 | 0.73 | |
| 1-year return as of 2026-08-07 close | +15.3% | -24.4% | ATRC higher |
Fundamentals: market data, as of 2026-08-09. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.